This company has been marked as potentially delisted and may not be actively trading. Edge Therapeutics (EDGE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock EDGE vs. ELAN, PBH, RYTM, PTCT, PRGO, RARE, RNA, ZLAB, AKRO, and MRUSShould you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include Elanco Animal Health (ELAN), Prestige Consumer Healthcare (PBH), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Perrigo (PRGO), Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), Zai Lab (ZLAB), Akero Therapeutics (AKRO), and Merus (MRUS). These companies are all part of the "medical" sector. Edge Therapeutics vs. Elanco Animal Health Prestige Consumer Healthcare Rhythm Pharmaceuticals PTC Therapeutics Perrigo Ultragenyx Pharmaceutical Avidity Biosciences Zai Lab Akero Therapeutics Merus Elanco Animal Health (NYSE:ELAN) and Edge Therapeutics (NASDAQ:EDGE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking. Does the media favor ELAN or EDGE? In the previous week, Elanco Animal Health had 13 more articles in the media than Edge Therapeutics. MarketBeat recorded 13 mentions for Elanco Animal Health and 0 mentions for Edge Therapeutics. Elanco Animal Health's average media sentiment score of 0.65 beat Edge Therapeutics' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Overall Sentiment Elanco Animal Health Positive Edge Therapeutics Neutral Do insiders & institutionals have more ownership in ELAN or EDGE? 97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 28.0% of Edge Therapeutics shares are owned by institutional investors. 0.9% of Elanco Animal Health shares are owned by company insiders. Comparatively, 37.1% of Edge Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer ELAN or EDGE? Elanco Animal Health currently has a consensus price target of $14.67, indicating a potential upside of 73.69%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, research analysts plainly believe Elanco Animal Health is more favorable than Edge Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elanco Animal Health 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43Edge Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ELAN or EDGE more profitable? Elanco Animal Health has a net margin of 4.60% compared to Edge Therapeutics' net margin of 0.00%. Elanco Animal Health's return on equity of 6.78% beat Edge Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elanco Animal Health4.60% 6.78% 3.03% Edge Therapeutics N/A -81.29%-56.92% Which has more risk & volatility, ELAN or EDGE? Elanco Animal Health has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Edge Therapeutics has a beta of 3.65, meaning that its share price is 265% more volatile than the S&P 500. Which has higher valuation & earnings, ELAN or EDGE? Edge Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElanco Animal Health$4.44B0.94-$1.23B$0.6712.60Edge TherapeuticsN/AN/A-$40.86MN/AN/A Does the MarketBeat Community favor ELAN or EDGE? Edge Therapeutics received 35 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 66.79% of users gave Edge Therapeutics an outperform vote while only 54.62% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformElanco Animal HealthOutperform Votes14254.62% Underperform Votes11845.38% Edge TherapeuticsOutperform Votes17766.79% Underperform Votes8833.21% SummaryElanco Animal Health beats Edge Therapeutics on 10 of the 15 factors compared between the two stocks. Get Edge Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDGE vs. The Competition Export to ExcelMetricEdge TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.10B$6.46B$5.32B$7.35BDividend YieldN/A3.21%5.47%4.31%P/E RatioN/A6.9521.9417.82Price / SalesN/A231.01380.9497.72Price / CashN/A65.6738.3134.64Price / Book36.865.936.453.98Net Income-$40.86M$143.22M$3.22B$247.81M Edge Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDGEEdge TherapeuticsN/A$35.01+0.3%N/A+1,107.3%$1.10BN/A0.00N/ANews CoverageELANElanco Animal Health4.3525 of 5 stars$8.11+0.2%$14.67+80.8%-34.8%$4.03B$4.44B20.319,800News CoveragePBHPrestige Consumer Healthcare4.1678 of 5 stars$80.13+0.4%$93.33+16.5%+15.0%$3.97B$1.12B18.79540Positive NewsRYTMRhythm Pharmaceuticals3.963 of 5 stars$61.10-0.4%$74.92+22.6%+62.4%$3.86B$130.13M-14.11140Analyst RevisionPositive NewsPTCTPTC Therapeutics3.865 of 5 stars$46.41flat$63.77+37.4%+87.2%$3.66B$806.78M-7.811,410Upcoming EarningsShort Interest ↑News CoveragePRGOPerrigo4.8523 of 5 stars$25.16+0.1%$33.00+31.2%-17.7%$3.43B$4.37B-21.508,900News CoveragePositive NewsRAREUltragenyx Pharmaceutical4.5196 of 5 stars$34.92-0.2%$92.79+165.7%-15.8%$3.28B$560.23M-5.511,310Analyst RevisionNews CoveragePositive NewsRNAAvidity Biosciences2.1801 of 5 stars$25.95+0.7%$66.69+157.0%+17.3%$3.14B$10.90M-9.06190Positive NewsZLABZai Lab2.8641 of 5 stars$28.35-2.0%$47.37+67.1%+105.0%$3.13B$398.99M-10.241,950Gap UpAKROAkero Therapeutics4.2284 of 5 stars$36.77-1.8%$76.29+107.5%+81.3%$2.93BN/A-9.8230Insider TradePositive NewsMRUSMerus2.7271 of 5 stars$42.44+1.3%$85.31+101.0%+8.2%$2.93B$36.13M-10.7437News CoveragePositive News Related Companies and Tools Related Companies Elanco Animal Health Competitors Prestige Consumer Healthcare Competitors Rhythm Pharmaceuticals Competitors PTC Therapeutics Competitors Perrigo Competitors Ultragenyx Pharmaceutical Competitors Avidity Biosciences Competitors Zai Lab Competitors Akero Therapeutics Competitors Merus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDGE) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
